ICAAC 2010
Elvitegravir 'Quad' Single-tablet Regimen Shows Continued HIV Suppression at 48 Weeks
- Details
- Category: HIV Treatment
- Published on Tuesday, 14 September 2010 16:46
- Written by Liz Highleyman
Gilead Science's experimental "Quad" pill -- a once-daily single-tablet coformulation containing the new integrase inhibitor elvitegravir, the novel boosting agent cobicistat (GS 9350), and tenofovir plus emtricitabine (the drugs in the Truvada pill) -- continued to demonstrate potent antiviral activity and good tolerability at 48 weeks, according to data presented this week at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2010). In a second comparison, cobicistat worked as well as ritonavir as a booster for atazanavir, with similar changes in kidney function.
New NRTI Festinavir Exhibits Good Anti-HIV Activity and Safety in Phase 1b/2a Study
- Details
- Category: HIV Treatment
- Published on Tuesday, 14 September 2010 13:46
- Written by Liz Highleyman
The new nucleoside reverse transcriptase inhibitor (NRTI) festinavir, or OBP-601, demonstrated good antiviral activity, lowering HIV viral load by more than 1 log over 10 days, researchers reported this week at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2010) in Boston. The new drug, which is related to stavudine (d4T, Zerit), was associated with few serious drug-related adverse events in this short-term study, but longer clinical trials are needed.
Web Design and Development by